Evidence map›Paper›PMID 34115916›Full record

ArticleCancer science2021

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma.

Yuta Kodama, Ichidai Tanaka, Tatsuhiro Sato, Kazumi Hori, Soei Gen, Masahiro Morise, Daisuke Matsubara, Mitsuo Sato, Yoshitaka Sekido, Naozumi Hashimoto

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Design, synthesis, conformational analysis, and biological activity of CαJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  6. Article
  7. Roles of the Oxytocin Receptor (OXTR) in Human Diseases.International journal of molecular sciences · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yuta KodamaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ichidai TanakaDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0002-5517-0598
Tatsuhiro SatoDivision of Cancer Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Kazumi HoriDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Soei GenDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahiro MoriseDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Daisuke MatsubaraDepartment of Diagnostic Pathology, Tsukuba University, Tsukuba, Japan.
Mitsuo SatoDepartment of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0001-5458-9576
Yoshitaka SekidoDivision of Cancer Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Naozumi HashimotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0003-2337-629X
Nagoya University · JPAichi Cancer Center · JPUniversity of Tsukuba · JP

Funding

Japan Agency for Medical Research and Development Grant Number (JP 20lm0203005j0004)Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (B) 20H03The Nitto Foundation Nitto Foundation
6 · The paper itself

Abstract

Malignant mesothelioma (MM) is one of the most aggressive tumors. We conducted bioinformatics analysis using Cancer Cell Line Encyclopedia (CCLE) datasets to identify new molecular markers in MM. Overexpression of oxytocin receptor (OXTR), which is a G-protein-coupled receptor for the hormone and neurotransmitter oxytocin, mRNA was distinctively identified in MM cell lines. Therefore, we assessed the role of OXTR and its clinical relevance in MM. Kaplan-Meier and Cox regression analyses were applied to assess the association between overall survival and OXTR mRNA expression using The Cancer Genome Atlas (TCGA) datasets. The function of OXTR and the efficacy of its antagonists were investigated in vitro and in vivo using MM cell lines. Consistent with the findings from CCLE datasets analysis, OXTR mRNA expression was highly increased in MM tissues compared with other cancer types in the TCGA datasets, and MM cases with high OXTR expression showed poor overall survival. Moreover, OXTR knockdown dramatically decreased MM cell proliferation in cells with high OXTR expression via tumor cell cycle disturbance, whereas oxytocin treatment significantly increased MM cell growth. OXTR antagonists, which have high selectivity for OXTR, inhibited the growth of MM cell lines with high OXTR expression, and oral administration of the OXTR antagonist, cligosiban, significantly suppressed MM tumor progression in a xenograft model. Our findings suggest that OXTR plays a crucial role in MM cell proliferation and is a promising therapeutic target that may broaden potential therapeutic options and could be a prognostic biomarker of MM.

Indexed as

AnimalsBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Knockdown TechniquesHEK293 CellsHumansMesothelioma, MalignantMiceMice, Inbred BALB CMice, NudeOxytocinPyridinesReceptors, OxytocinRNA, MessengerBiomarkers, TumorcligosibanOXTR protein, humanOxytocinPyridinesReceptors, OxytocinRNA, MessengerTriazolesG1 phase cell cycle checkpointsG-protein-coupled receptorsmalignant mesotheliomaoxytocin receptoroxytocin receptor antagonists

Identifiers

PMID34115916
PMCPMC8409407
OpenAlexW3168911116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.